Abelacimab, formerly known as MAA868, represents a groundbreaking approach to preventing thrombosis. This antiplatelet agent is a selective monoclonal protein that inhibits the integrin αIIbβ3, a key player in https://blanchedxcj797445.blog5.net/92115477/abelacimab-maa868-a-deep-examination-into-the-new-thrombosis-treatment